Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 5/2021

01-05-2021 | Multiple Myeloma | Letter to the Editor

Flow cytometry analysis of peripheral Tregs in patients with multiple myeloma under lenalidomide maintenance

Authors: Kenji Nozaki, Yuki Fujioka, Daisuke Sugiyama, Jun Ishikawa, Masato Iida, Masaru Shibata, Satoru Kosugi, Hiroyoshi Nishikawa, Hirohiko Shibayama

Published in: International Journal of Hematology | Issue 5/2021

Login to get access

Excerpt

Studies show that numbers of regulatory T cells (Tregs) increase in the peripheral blood of patients with multiple myeloma (MM) undergoing lenalidomide treatment [1]. However, as lenalidomide is known to cause antitumor effects, it is unclear whether the Tregs present in elevated numbers in patients with MM are truly functional, owing to the different gating strategies used for Tregs and the lack of analyses of Treg subsets. Moreover, the effects of lenalidomide on Tregs and effector T cells remain unknown. To investigate these effects, we measured the numerical and phenotypic features of peripheral T cells at regular intervals during lenalidomide maintenance (LM). …
Literature
1.
Minnema MC, Van der Veer MS, Aarts T, Emmelot M, Mutis T, Lokhorst HM. Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells. Leukemia. 2009;23(3):605–7.CrossRef
2.
Fostier K, Caers J, Meuleman N, Broos K, Corthals J, Thielemans K, et al. Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation. Oncotarget. 2018;9(29):20476–89.CrossRef
3.
Kim IK, Kim BS, Koh CH, Seok JW, Park JS, Shin KS, et al. Glucocorticoid-induced tumor necrosis factor receptor-related protein co-stimulation facilitates tumor regression by inducing IL-9-producing helper T cells. Nat Med. 2015;21(9):1010–7.CrossRef
Metadata
Title
Flow cytometry analysis of peripheral Tregs in patients with multiple myeloma under lenalidomide maintenance
Authors
Kenji Nozaki
Yuki Fujioka
Daisuke Sugiyama
Jun Ishikawa
Masato Iida
Masaru Shibata
Satoru Kosugi
Hiroyoshi Nishikawa
Hirohiko Shibayama
Publication date
01-05-2021
Publisher
Springer Singapore
Published in
International Journal of Hematology / Issue 5/2021
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-021-03093-y

Other articles of this Issue 5/2021

International Journal of Hematology 5/2021 Go to the issue

Original Article

Impact of 2 Gy γ-irradiation on the hallmark characteristics of human bone marrow-derived MSCs

Original Article

Prognostic impact of 18F-FDG PET/CT in patients with multiple myeloma presenting with renal impairment

Images in Hematology

EBV-positive diffuse large B-cell lymphoma, not otherwise specified masking Richter syndrome

Case Report

Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma with HTLV-1-associated myelopathy

Images in Hematology

Relapsed RUNX1-RUNX1T1-positive acute myeloid leukemia with pseudo-Chediak-Higashi granules

Letter to the Editor

Latest trends in the incidence of Helicobacter pylori-uninfected gastric mucosa-associated lymphoid tissue lymphoma at the Cancer Institute Hospital, Japan
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits